Estudo para explorar o efeito terapêutico da eluxadolina no tratamento da síndrome do intestino irritável com diarreia em crianças
Fase 2, randomizado, duplo-cego, controlado por placebo, grupo paralelo, estudo de variação de dose para avaliar a segurança e a eficácia da eluxadolina em participantes pediátricos (idade de 6 a 17 anos) com síndrome do intestino irritável com diarreia (IBS-D)
The primary objectives of this study are to explore the therapeutic effect of eluxadoline in treating irritable bowel syndrome with diarrhea (IBS-D) in pediatric participants 6-17 years of age, to evaluate the pharmacokinetics of eluxadoline in pediatric participants with IBS-D, and to evaluate the safety and tolerability of eluxadoline in pediatric participants with IBS-D. Enrollment of 12-17 years old age group is closed, enrollment of the 6-11 years old age group will continue.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
-
Wuppertal, Alemanha, 42283
- HELIOS Klinikum Wuppertal /ID# 237322
-
-
-
-
-
Kozloduy, Bulgária, 3320
- MHATSv.Ivan Rilski /ID# 235399
-
Plovdiv, Bulgária, 4001
- University Hospital Plovdiv /ID# 235450
-
-
Gabrovo
-
Sevlievo, Gabrovo, Bulgária, 5400
- Medical center 1 Sevlievo /ID# 237473
-
-
-
-
-
Edmonton, Canadá, T6G 1C9
- Duplicate_Edmonton Clinic Health Academy (ECHA) /ID# 234917
-
Winnepeg, Canadá, R3E 3P4
- Manitoba Institute of Child Health /ID# 235448
-
-
-
-
-
Valencia, Espanha, 46017
- Hospital Universitario Dr. Peset /ID# 236755
-
-
-
-
Arkansas
-
Hot Springs, Arkansas, Estados Unidos, 71913
- HealthStar Research of Hot Springs PLLC /ID# 234609
-
Little Rock, Arkansas, Estados Unidos, 72212-4187
- Applied Research Center of Arkansas /ID# 238070
-
-
California
-
Corona, California, Estados Unidos, 92879
- Kindred Medical Institute, LLC /ID# 237368
-
Garden Grove, California, Estados Unidos, 92845
- Duplicate_VVCRD Research /ID# 234606
-
Paramount, California, Estados Unidos, 90723
- Duplicate_Center for Clinical Trials LLC /ID# 234630
-
-
Florida
-
Miami, Florida, Estados Unidos, 33130
- Sunrise Research Institute /ID# 237382
-
Miami, Florida, Estados Unidos, 33155
- South Miami Medical & Research Group Inc. /ID# 234655
-
Miami, Florida, Estados Unidos, 33165
- Valencia Medical & Research Center /ID# 234672
-
Miami, Florida, Estados Unidos, 33174
- Florida Research Center, Inc. /ID# 236514
-
Miami Lakes, Florida, Estados Unidos, 33016
- Duplicate_Wellness Clinical Research /ID# 237401
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30315
- Global Research Associates /ID# 234646
-
Atlanta, Georgia, Estados Unidos, 30342
- Children's Ctr Digestive, US /ID# 237575
-
Stockbridge, Georgia, Estados Unidos, 30281
- Sleep Care Research Institute d/b/a Clinical Research Institute /ID# 236343
-
-
Illinois
-
Park Ridge, Illinois, Estados Unidos, 60068
- Advocate Children's Hospital-Park Ridge /ID# 235388
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Indiana University Health Riley Hospital for Children /ID# 235400
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40517
- Michael W. Simon, MD, PSC /ID# 236517
-
-
Maryland
-
New Market, Maryland, Estados Unidos, 21774-6154
- Frederick County Pediatrics /ID# 234519
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55413-2195
- MNGI Digestive Health, P. A. /ID# 238057
-
-
New Jersey
-
Marlton, New Jersey, Estados Unidos, 08053
- Celen Medical Group Corp - Marlton /ID# 234922
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73106
- IPS Research Company /ID# 237672
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104-4319
- Children's Hospital of Philadelphia - Main /ID# 234313
-
Pittsburgh, Pennsylvania, Estados Unidos, 15236
- Preferred Primary Care Physicians, Inc. /ID# 236436
-
-
Texas
-
Fort Worth, Texas, Estados Unidos, 76104
- Cook Children's Med. Center /ID# 237537
-
Houston, Texas, Estados Unidos, 77030-2608
- Texas Children's Hospital /ID# 238304
-
San Antonio, Texas, Estados Unidos, 78215
- Sun Research Institute /ID# 236933
-
-
West Virginia
-
Morgantown, West Virginia, Estados Unidos, 26506
- West Virginia University Hospitals /ID# 256841
-
-
-
-
North Holland
-
Amsterdam, North Holland, Holanda, 1105 AZ
- Duplicate_Academisch Medisch Centrum /ID# 237117
-
-
-
-
-
Budapest, Hungria, 1125
- Eszak-Kozep-budai Centrum, Uj Szent Janos Korhaz /ID# 236993
-
Sopron, Hungria, 9400
- Soproni Erzsebet Oktato Korhaz es Rehabilitacios Intezet /ID# 237341
-
Székesfehérvár, Hungria, 8000
- Vita Verum Medical Bt. /ID# 234321
-
-
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polônia, 30-539
- Specjalistyczne Gabinety Sp. z o.o. /ID# 236347
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polônia, 00-189
- Centrum Zdrowia MDM /ID# 237269
-
Warsaw, Masovian Voivodeship, Polônia, 04-730
- Duplicate_Instytut Pomnik - Centrum Zdrowia Dziecka /ID# 234311
-
-
Podkarpackie Voivodeship
-
Rzeszów, Podkarpackie Voivodeship, Polônia, 35-302
- Korczowski Bartosz Gabinet Lekarski /ID# 234683
-
-
Pomeranian Voivodeship
-
Gdansk, Pomeranian Voivodeship, Polônia, 80-803
- Copertnicus Podmiot Leczniczy Sp. z o.o. /ID# 235656
-
-
Łódź Voivodeship
-
Lodz, Łódź Voivodeship, Polônia, 93-338
- Instytut Centrum Zdrowia Matki Polki /ID# 237438
-
-
-
-
-
Blackpool, Reino Unido, FY3 8NR
- Blackpool Teaching Hospitals NHS Foundation Trust /ID# 237273
-
-
Greater London
-
London, Greater London, Reino Unido, SE5 9RS
- Kings College Hospital NHS Foundation Trust /ID# 236305
-
-
Lancashire
-
Manchester, Lancashire, Reino Unido, M13 9WL
- Duplicate_Manchester University NHS Foundation Trust /ID# 234663
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Participant must provide written or verbal informed assent and the parent/guardian/LAR must provide written informed consent before the initiation of any study-specific procedures.
-
Participant is a male or female outpatient, 6 to 17 years of age inclusive, at the time the participant provides assent for the study and parent/guardian/LAR has provided signed consent.
-
Participant is able to read and understand the assessments in the eDiary. If the participant is 6 to 11 years of age and does not meet this criterion, the interviewer-administered version of the eDiary must be used and the parent/guardian/LAR or caregiver who will be administering the interviewer-administered version of the eDiary must be able to read and understand the assessments in the eDiary and must undergo training.
-
Female participants must not be pregnant, breastfeeding, or considering becoming pregnant during the study or for approximately 30 days after the last dose of study drug. Female participants of childbearing potential must have a negative serum pregnancy test at Visit 1 (screening) and a negative urine pregnancy test at Visit 3 (randomization) prior to dosing.
-
Female participants of childbearing potential must practice at least 1 protocol-specified method of birth control, that is effective from Study Day 1 through at least 30 days after the last dose of study drug. Local practices may require 2 methods of birth control. Female participants of non-childbearing potential do not need to use birth control.
-
Participant has a diagnosis of IBS-D as defined by the modified Rome IV child/adolescent criteria: Must include all of the following:
-- Abdominal pain at least 4 days per month over at least 2 months associated with one or more of the following:
-
Related to defecation
-
A change in frequency of stool
-
A change in form (appearance) of stool
- After appropriate evaluation, the symptoms cannot be fully explained by another medical condition.
- Participant has predominantly diarrheal stool symptoms defined as Bristol stool types 6 or 7 for more than 25% of bowel movements and Bristol stool types 1 or 2 for less than 25% of bowel movements that occur in the absence of laxative.
-
Participant may be newly diagnosed with IBS-D by the investigator at Visit 1. All criteria for diagnosis must be fulfilled for at least 2 months prior to Visit 1 (screening).
-
-
Participant has been compliant with the eDiary by completing both the morning and evening assessments for at least 8 out of the 14 days immediately preceding Visit 3 (randomization).
-
Participant has an average daytime abdominal pain score greater than or equal to 1.0 over the 2 weeks prior to randomization.
-
Participant has at least 1 daytime bowel movement with a consistency of Type 6 or Type 7 on the pediatric Bristol Stool Form Scale (p-BSFS) on at least 2 days per week during the 2 weeks immediately prior to randomization and that occurs in the absence of laxatives.
Exclusion Criteria:
-
Participant has no gallbladder, (ie, agenesis of the gallbladder or cholecystectomy).
-
Participant has had any of the following surgeries:
- Any abdominal surgery within the 3 months prior to Screening; or
- A history of major gastric, hepatic, pancreatic, or intestinal surgery. (Note: appendectomy, hemorrhoidectomy, or polypectomy greater than 3 months post-surgery are allowed. For the purposes of this study, laparoscopic surgeries without complication are considered minor and non-exclusionary, provided the condition for which the surgery was performed was not exclusionary.)
-
Participant has a history of chronic or severe constipation or sequelae from constipation, or known or suspected mechanical GI obstruction or pseudo obstruction.
-
Participant has a history or current diagnosis of constipation with encopresis.
-
Participant meets the child/adolescent Rome IV criteria of IBS with constipation, IBS with constipation and diarrhea (mixed), unspecified IBS, or functional constipation.
-
Participant has a history of intestinal obstruction, stricture, toxic megacolon, GI perforation, fecal impaction, gastric banding, bariatric surgery, adhesions, ischemic colitis, or impaired intestinal circulation.
-
Participant has a documented history of hepatic impairment as defined by Child-Pugh Classification Grade A, B or C.
-
Participant has a history or current diagnosis of inflammatory or immune-mediated lower GI disorders including inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, microscopic colitis). Crohn's disease affecting the upper GI tract would also be exclusionary.
-
Participant has celiac disease, or a positive serological test for celiac disease and the condition has not been ruled out by endoscopic biopsy.
-
Participant has any congenital and/or acquired malabsorption syndrome (eg, Shwachman-Diamond syndrome).
-
Participant has a history of a microbiologically documented (ie, stool culture or medical history) GI infection within 3 months prior to Screening.
-
Participant has a known lactose or fructose intolerance that is associated with diarrhea, abdominal pain or discomfort, and that could confound assessments in the study.
-
Participant has a history of diverticulitis within 3 months prior to Screening.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Eluxadoline 25mg
Eluxadoline 25mg, oral administration, twice daily |
Oral tablets
Outros nomes:
|
|
Experimental: Eluxadoline 50mg
Eluxadoline 50mg, oral administration, twice daily |
Oral tablets
Outros nomes:
|
|
Experimental: Eluxadoline 100mg
Eluxadoline 100mg, oral administration, twice daily |
Oral tablets
Outros nomes:
|
|
Experimental: Placebo
Dose-matched placebo, oral administration, twice daily |
Oral tablets |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change from baseline in stool consistency averaged over the 4-week Treatment Period
Prazo: Baseline (2 Weeks prior to randomization) to Week 4
|
Stool consistency will be assessed using the Pediatric Bristol Stool Form Scale (p-BSFS) on a range from 1 (Hard Lumps) to 7 (Watery). |
Baseline (2 Weeks prior to randomization) to Week 4
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change from baseline in stool consistency for daily daytime and nighttime stool consistency scores
Prazo: Baseline (2 Weeks prior to randomization) to Week 4
|
Stool consistency will be assessed using the Pediatric Bristol Stool Form Scale (p-BSFS) on a range from 1 (Hard Lumps) to 7 (Watery). |
Baseline (2 Weeks prior to randomization) to Week 4
|
|
Change from baseline for daytime, nighttime, and 24-hour abdominal pain scores
Prazo: Baseline (2 Weeks prior to randomization) to Week 4
|
Abdominal Pain is scored on a five-point ordinal scale, with 0 meaning no pain, and 4 meaning a lot of pain. |
Baseline (2 Weeks prior to randomization) to Week 4
|
|
Change from baseline for daytime, nighttime, and 24-hour bowel movement frequency
Prazo: Baseline (2 Weeks prior to randomization) to Week 4
|
Change from baseline in the number of bowel movements. |
Baseline (2 Weeks prior to randomization) to Week 4
|
|
Change from baseline for daytime, nighttime, and 24 hour urgency-free days
Prazo: Baseline (2 Weeks prior to randomization) to Week 4
|
Change from baseline in the number of urgency free days in a week. |
Baseline (2 Weeks prior to randomization) to Week 4
|
|
Change from baseline for daytime, nighttime, and 24 hour number of fecal incontinence-free days
Prazo: Baseline (2 Weeks prior to randomization) to Week 4
|
Change from baseline in the number of fecal incontinence-free days in a week. |
Baseline (2 Weeks prior to randomization) to Week 4
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: ABBVIE INC., AbbVie
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 3030-202-002
- 2017 (Concessão/Contrato do NIH dos EUA)
- 2017-003770-14 (Número EudraCT)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Prazo de Compartilhamento de IPD
For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Critérios de acesso de compartilhamento IPD
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CSR
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .